Poolbeg Pharma’s (POLB) “House Stock” Rating Reaffirmed at Shore Capital Group

Poolbeg Pharma (LON:POLB)‘s stock had its “house stock” rating reissued by research analysts at Shore Capital Group in a research note issued on Monday,London Stock Exchange reports.

Poolbeg Pharma Stock Performance

Shares of LON:POLB opened at GBX 7.40 on Monday. The business has a 50-day simple moving average of GBX 6.35 and a two-hundred day simple moving average of GBX 5.07. Poolbeg Pharma has a fifty-two week low of GBX 2.50 and a fifty-two week high of GBX 9. The firm has a market cap of £52.18 million, a price-to-earnings ratio of -7.87 and a beta of 1.81.

Poolbeg Pharma (LON:POLB) last issued its quarterly earnings data on Tuesday, April 28th. The company reported GBX (0.94) earnings per share for the quarter. As a group, research analysts predict that Poolbeg Pharma will post -0.68 earnings per share for the current year.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.